Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 254 participants.

Also called NCT02057172

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 254 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02057172
Other papers using this trial's data
  • Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide Diabetes care, 2019-09 DOI, PubMed 31320446

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02057172. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Intervention (Drug)
HM11260C
Intervention (Drug)
liraglutide
Intervention (Drug)
Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct02057172
Content hash
3e3d8bf33cca0e87af4534d5c890be0053dad7f0e59bfb8727d6a55ef8aa3974